**SUPPLEMENTARY MATERIAL**

**Table I: adverse events reported during treatment with anti-TNFα. The table specifies the number and type of adverse events, and if they leads a anti-TNFα discontinuation.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **AFTER INDUCTION** | **Anti-TNfα discontinued** | **30 WEEKS** | **Anti-TNfα discontinued** | **52 WEEKS** | **Anti-TNfα discontinued** |
|  | **N (%)** | **Type of adverse events** |  | **N (%)** | **Type of adverse events** |  | **N** | **Type of adverse events** |  |
| **ADA UC** | 2 (6.4) | Frequent Flu Syndromes | No | 2 (6.7) | Injection site reaction | No | 3 (10.7) | Tonsillitis | No |
| Folliculitis | No | Urinary tract infections | No | Erythema  | No |
| Erythema | No |
| **ADA CD** | 2 (6.7) | Dyspnea, cough and chest pain | Yes | 5 (17.2) | Dermatitis | No | 0 | - | - |
| Paresthesia | No | Inverse psoriasis | Yes |
| Conjunctivitis, blepharitis, vitreous detachment | Yes |
| Injection site reaction | No |
| Injection site reaction | No |
| **IFX Originator** **UC** | 0 | **-** | - | 2 (6.7) | Skin rash | No | **3 (10)** | Dermatitis | No |
| Urinary tract infections | No | Urinary tract infections | No |
| Urinary tract infections | No |
| **IFX Originator** **CD** | 2 (6.7) | Melanoma in situ | Yes | 6 (20.7) | Psoriasis | No | 4 (14.8) | Psoriasis | Yes |
| Urinary tract infections | No | Erythema and itch | No | Psoriasis | No |
| Urinary tract infections | No | Psoriasis | No |
| Psoriasis | No | Arthralgia | No |
| Psoriasis | No |
| Dizziness | No |
| **IFX Biosimilar** **UC** | 4 (14.3) | Total body eczema | No | 2 (7.7) | Persistent vaginitis | No | 2 (7.7) | Skin rash | No |
| Skin rash | No | Skin rash | Yes | Persistent vaginitis | Yes |
| Inguinal eczema | No |
| Frequent bronchitis | No |
| **IFX Biosimilar** **CD** | 4 (13.3) | Amnesia | No | 6 (20) | Biliary tract neoplasia | Yes | 8 (34.8) | Herpes labialis | No |
| Erythema | No | Skin rash | No | Maculo-papular rash | Yes |
| Urticaria | No | Tonsillitis | Yes | Arthralgia | No |
| Urticaria | No | Lung carcinoma | Yes | Headache | No |
| Flushing and dyspnea | No | Flushing, tachycardia | Yes |
| Asthenia, weight gain | No | Arthralgia | No |
| Skin rash | No |
| Skin rash | Yes |

**Table II: Anti-TNFα optimization treatment among patients with Ulcerative Colitis (UC) and Crohn Disease (CD) treated with Infliximab (IFX) Originator, Infliximab (IFX) Biosimilar, Adalimumab (ADA) after induction, at 30 and 52 weeks.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **N** | **Type of Anti-TNFα** | **After Induction** | **30 weeks** | **52 weeks** |
|
| **N**  | **p** | **N**  | **P** | **N**  | **P** |
| **31** | **ADA UC**40 mg/2 weeks40 mg/week80 mg/2 weeks | 292- | 0.97 | 228- | 0.68 | 1611- | 0.51 |
| **30** | **ADA CD**40 mg/2 weeks40 mg/week80 mg/2 weeks | 282- | 245- | 178- |
| **30** | **IFX Originator UC**5 mg/8 weeks10 mg/8 weeks5 mg/6 weeks5 mg/4 weeks | 29-1- | 0.31 | 24-51 | **0.03** | 22-71 | 0.10 |
| **30** | **IFX Originator CD**5 mg/8 weeks10 mg/8 weeks5 mg/6 weeks5 mg/4 weeks | 30--- | 30--- | 26-2- |
| **28** | **IFX Biosimilar UC**5 mg/8 weeks10 mg/8 weeks5 mg/6 weeks5 mg/4 weeks | 26--2 | 0.14 | 23-12 | 0.38 | 17-43 | 0.92 |
| **30** | **IFX Biosimilar CD**5 mg/8 weeks10 mg/8 weeks5 mg/6 weeks5 mg/4 weeks | 30--- | 23133 | 16536 |